Visit our news section for more articles.
News Our full Mednous news archive Appointments Latest industry appointments Events A list of upcoming industry events
Evernow Publishing Ltd Privacy Policy. Read more.
Subscribe to MedNous and get ahead in the business of medical innovation. Subscribe now.
The latest MedNous journal. Subscribe to download.
Denmark
Genmab A/S moved a step closer towards its goal of becoming a fully integrated biotech in 2020 following a licensing deal with AbbVie Inc which pushed revenue higher and put the Danish company on course to co-develop three bispecific antibody compounds. The agreement, concluded in June, delivered an upfront payment of $750 million, helping to deliver significantly higher revenue for the year.
United States
Merck & Co Inc has voluntarily withdrawn the metastatic small cell lung cancer indication for Keytruda (pembrolizumab) following the results of a Phase 3 study which didn’t support the terms of its earlier accelerated approval from the US Food and Drug Administration. The FDA awards accelerated approvals to certain drugs, based on surrogate endpoints, but confirmation of clinical benefit needs to be verified in subsequent trials.
United Kingdom
UK-based Oxular Ltd has secured $37 million in venture finance to advance its lead product for diabetic macular edema (DME) into Phase 2 as well as support earlier stage ophthalmologic products. The venture capital firm Forbion led the financing, which included existing investors IP Group, NeoMed and V-Bio Ventures.
United States
United States
United States
United Kingdom
Belgium
Norway
United Kingdom
Netherlands
United Kingdom
Netherlands
Visit our news section for more articles.
News Our full Mednous news archive Appointments Latest industry appointments Events A list of upcoming industry events
© 2021 Evernow Publishing Ltd. Powered by Drupal.